Primary myelofibrosis (pmf)
Drug research and approvals for primary myelofibrosis (pmf): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 8 studies of primary myelofibrosis (pmf) are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, FDA has 3 approved and 1 open orphan designations naming it, and the EU has 5 authorised medicines for it.
- Recruiting worldwide: 8
- Trials authorized in Canada: 8
- FDA orphan approvals: 3
- EU medicines: 5
Recruiting Now
Newest start dates first, of 8 recruiting on ClinicalTrials.gov ↗- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)NCT07357727 · Phase 3 · Novartis Pharmaceuticals · starts May 27, 2026
- Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative NeoplasmNCT07590986 · Not reported · Université Catholique de Louvain · starts May 1, 2026
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsNCT07469891 · Phase 1 · Prelude Therapeutics Incorporated · starts Apr 29, 2026
- MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With…NCT07362225 · Not reported · MPN Research Foundation · starts Sep 26, 2025
- Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisNCT06770842 · Phase 2 · The University of Hong Kong · starts Mar 1, 2025
- A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis…NCT06343805 · Phase 1 · Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · starts Oct 3, 2024
- Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera…NCT06327100 · Phase 1 / Phase 2 · M.D. Anderson Cancer Center · starts Aug 1, 2024
- Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)NCT05835466 · Phase 2 · Icahn School of Medicine at Mount Sinai · starts Jul 24, 2023
Trials Authorized in Canada
Newest first; search them all in Canada trials| May 1, 2025 | A randomized, double-blind, placebo-controlled multicenter phase 3 clinical study to assess efficacy and safety of ropeginterferon alfa-2b (p1101) in adult…ROPEGINTERFERON ALFA-2B-NJFT (P1101) | PharmaEssentia | Ongoing |
| Nov 29, 2019 | A randomized, controlled phase 3 study of pacritinib versus physician's choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or…PACRITINIB (SB1518) / RUXOLITINIB / HYDROXYUREA / DANAZOL | Sobi | Ongoing |
| Jul 27, 2018 | An open-label, phase 2a/2b study of krt-232 in subjects with primary myelofibrosis (pmf), post¿polycythemia vera mf (post¿pv-mf), or post¿essential…NAVTEMADLIN (KRT-232) | KARTOS THERAPEUTICS INC | Ongoing |
| Feb 28, 2018 | Extended access of momelotinib for subjects with primary myelofibrosis (pmf) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis…MOMELOTINIB | GSK | Closed |
| Jan 10, 2017 | A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients.JAKAVI (INC424, RUXOLITINIB) | Novartis Pharmaceuticals Corporation | Closed |
| May 9, 2014 | A randomized controlled phase 3 study of oral pacritinib versus best available therapy in patients with thrombocytopenia and primary myelofibrosis,…PACRITINIB (SB1518) | CTI BIOPHARMA CORP | Ongoing |
| Feb 6, 2014 | A phase 3, randomized, double-blind active-controlled study evaluating momelotinib vs. ruxolitinib in subjects with primary myelofibrosis (pmf) or…MOMELOTINIB | Gilead Sciences | Closed |
| Jul 19, 2013 | A phase 2, open-label, prospective study of prm-151 in subjects with primary myelofibrosis (pmf), post-polycythemia vera mf (post-pv mf), or post-essential…PRM-151 SOLUTION FOR INJECTION (RO7490677) | Roche | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Feb 28, 2022 | VonjoTreatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia)… | Sobi, Inc. | Approved |
| Aug 16, 2019 | INREBICINREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or… | Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene Corporation | Approved |
| Nov 16, 2011 | JakafiTreatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis… | Incyte Corporation | Approved |
| Dec 14, 2020 | Jaktinib Dihydrochloride MonohydrateTreatment of Primary Myelofibrosis (PMF) or Post-polycythemia Vera/Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | Designated |
Medicines Authorised in the EU
Newest first| Nov 12, 2026 | Ruxolitinib Zentivaruxolitinib · generic | Zentiva k.s. | EMA ↗ |
| Sep 18, 2026 | Ruxolitinib Viatrisruxolitinib hemifumarate · generic | Viatris Limited | EMA ↗ |
| Jan 25, 2024 | Omjjaramomelotinib · orphan | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| Feb 8, 2021 | Inrebicfedratinib · orphan | Bristol Myers Squibb Pharma EEIG | EMA ↗ |
| Aug 23, 2012 | Jakaviruxolitinib | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA